The Fujian drug and device joint procurement center has published the “Fujian Fourth Round Drug Volume-Based Procurement (VBP) Document (draft proposal),” inviting public feedback until October 20, 2023. This initiative encompasses 50 chemical drugs and 24 Chinese patent drugs, with the procurement period set to last until December 31, 2025.
Procurement Criteria and Drug Categories
The selected procurement varieties are drugs characterized by large usage, high procurement amounts, abundant competition, and frequent clinical use. The chemical drugs, which include beraprost, vancomycin, procaterol, and lactulose, are categorized into Group A (non-competitive drugs) and Group B (other drugs) for price bidding. The agreed procurement quantity for antibacterial drugs is determined by 60% of the procurement demand of each group, while for other drugs, it is determined by 70% of the demand.
Bidding Process and Winning Criteria
The determination of non-competitive drugs must comply with the provisions of the “Notice of Fujian Provincial Medical Security Bureau on Further Improving the Joint Limited Price Sunshine Procurement of Drugs.” For groups with three or more filing manufacturers, the lowest quoted manufacturer will secure the bid and obtain 100% of the agreed procurement quantity. In groups with two or fewer filing manufacturers, the lowest quoted manufacturer must meet specific reduction conditions to win the bid.
Chinese Patent Drugs Inclusion
The Chinese patent drugs included in the procurement list, such as Lianhua Qingwen Oral Formulation and Compound Danshen Dropping Pills, will secure a spot if the valid quote does not exceed the quote limit or the lowest winning price from the previously winning bid.-Fineline Info & Tech
